is classified as an angiotensin II receptor antagonist drug that is used for treating conditions such as high blood pressure
. Eprosartan’s action focuses on the rennin-angiotensin system by decreasing the total peripheral resistance in two ways. It first blocks angiotensin II binding in AT1 receptors in the vascular smooth muscles
which causes vascular dilatation. Secondly, it inhibits the production of sympathetic norepinephrine
which further reduces the patient’s blood
As compared with the other angiotensin II receptor antagonists, eprosartan has been reported to be better tolerated than its counterpart enalapril
, especially among the geriatric population.
Eprosartan is marketed as Teveten by Abbott Laboratories in the United States. It is sometimes paired with hydrochlorothiazide
and marketed as Teveten HCT or Teveten Plus. Teveten is indicated for the treatment of hypertension
or high blood pressure.
The usual dose recommended in eprosartan administration is 600 mg once daily, if used as a single therapy drug (monotherapy) with patients found out to be non-volume depleted. Teveten may be administered once or twice daily with total daily doses that range from 400 – 800 mg. The maximum reduction in blood pressure may be achieved by most patients if eprosartan is taken within two to three weeks.
Side effects of eprosartan use may vary from patient to patient. However, most commonly reported side effects include dizziness
pains (athralgia), rhinitis
or inflamed nose
linings causing runny or blocked noses, flatulence
or excessive gas in the stomach
, increased levels of triglycerides in the blood stream (hypertriglyceridemia), hyperkalemia or an increase in potassium levels in the blood, headaches
, weakness, swelling
of the lips
, and low blood pressure.
Teveten has been found to be safely co-administered with other anti-hypertensive drugs when additional effects of lowering blood pressure is required, such as those of thiazide diuretics or calcium
channel blockers. Discontinuing eprosartan therapy has not been reported to a rebound in blood pressure increase.
Eprosartan/Teveten must be taken with a full stomach. Eprosartan is contraindicated in patients with hypersensitivity to the drug or its components. Dizziness and/or nausea may occur when taking eprosartan. Caution must be exercised when performing tasks that require focus and attention such as driving or machine operation.
As eprosartan works on the blood, people with ailments in the kidneys
function must undergo regular blood tests to check the levels of creatinine and potassium in their bloodstream while undergoing eprosartan therapy.
Caution must be exercised when taking eprosartan if patients are 75 years or older, have decreased kidney functions, have any history of heart
or blood vessel problems, and low fluid volumes or salt levels in the body due to diet, diarrhea
Eprosartan is not to be used with patients suffering from severe liver
impairment, severe heart and blood vessel problems. Pregnant women, or women planning to become pregnant must first consult a physician prior to eprosartan administration. Nursing mothers must also consult a doctor before taking eprosartan. The potential benefits the drug must be weighed against the risks it may pose to the fetus and the nursing infant. Eprosartan may be harmful to children because of its preservative – alcohol.
Eprosartan has the following structural formula:
• Molecular formula of eprosartan is C23H24N2O4S
• Chemical IUPAC Name is 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-imidazol-1-yl]methyl]benzoicacid
• Molecular weight is 424.514 g/mol
• Eprosartan available : 400mg tablets and 600mg tablets